Alignment Healthcare enters the back half of August with a striking contradiction at its core: short interest just posted its biggest single-day jump in months, yet the options market is tilting more bullish than at any point since late July.
The short side of this story moved fast this week. Short interest climbed 17.6% in a single session on August 25, reaching 11.7% of free float — a reading that had been drifting lower since peaking near 12.5% in late July. The move adds roughly 3.5 million shares to the short book in one day, reversing a gradual unwind that had brought SI down from above 25 million shares to around 20 million through most of August. What makes the jump more notable is that the borrow market shows almost no stress: cost to borrow sits at just 0.47%, and availability remains deep at 571% of short interest, well above even the 52-week low of 277%. Shorts are rebuilding with ease, not fighting for shares.
Options positioning sends the opposite message. The put/call ratio is running at 0.15, below its 20-day average of 0.18 and close to its lowest level of the past year — meaning call demand is outpacing puts by a wide margin. That's not the profile of a market bracing for further downside. The PCR has compressed steadily since mid-July, when it was running above 0.32. The divergence between a short book that's growing and an options market that's leaning long is the defining tension for ALHC this week.
The Street backdrop helps explain both sides of that argument. JP Morgan cut its price target to $22 from $26 on August 4, while maintaining an Overweight rating — a classic "we still believe, but the near-term is harder" trim. Raymond James went further, downgrading from Strong Buy to Outperform and cutting to $19, also in early August. Both moves followed the July 30 earnings print, which sent the stock down 18.8% in a single session and 26.8% over the subsequent five days. That kind of reaction leaves a mark: the stock has fallen 30% over the past month to $13.59. The mean analyst price target now implies roughly 77% upside from current levels — a gap that either signals deep value or reflects targets that haven't fully reset post-print. The bull case rests on Stars funding advantages and 2026 Medicare Advantage rate dynamics; bears point to payor data friction and elevated valuation multiples relative to EBITDA growth. The PE multiple has compressed nearly 12.5 points over the past 30 days, and price-to-book has fallen more than 4 turns, reflecting how quickly the repricing has moved.
Insider selling complicates the recovery narrative. CEO John Kao sold 298,000 shares at $13.88 on August 10 — $4.1 million worth — just days after the post-earnings collapse. President Dawn Maroney sold 177,000 shares at $20.83 on July 15, before the print, and another 5,000 shares at $14 on August 14. Across the top holders, BlackRock added 5.5 million shares in the most recent filing period, and Invesco added 2.8 million — suggesting institutional conviction on one side even as insiders reduce exposure. The 90-day net insider figure is technically positive in share terms due to option-related activity, but the cash sales are uniformly one-directional.
The ORTEX short score ticked up to 56.1 on August 25 from around 52.6 the prior week — a meaningful but not extreme reading. Earnings momentum factor scores remain strong at the 86th-87th percentile on a 30- and 90-day basis, suggesting analysts are still revising estimates upward even after the print. The next earnings event is scheduled for October 29, which means positioning will have roughly two months to evolve — and how the short rebuild of this week either holds or reverses through September is the clearest near-term signal to track.
See the live data behind this article on ORTEX.
Open ALHC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
